

Dineo Khabele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4297847/publications.pdf>

Version: 2024-02-01

47
papers

2,215
citations

361413

20
h-index

254184

43
g-index

47
all docs

47
docs citations

47
times ranked

4314
citing authors

#	ARTICLE	IF	CITATIONS
1	An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules. <i>Cell</i> , 2013, 154, 1151-1161.	28.9	615
2	Hdac3 Is Essential for the Maintenance of Chromatin Structure and Genome Stability. <i>Cancer Cell</i> , 2010, 18, 436-447.	16.8	305
3	Gynecologic cancer disparities: A report from the Health Disparities Taskforce of the Society of Gynecologic Oncology. <i>Gynecologic Oncology</i> , 2014, 133, 353-361.	1.4	171
4	Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 133, 599-606.	1.4	103
5	Inhibition of Histone Deacetylase 3 Causes Replication Stress in Cutaneous T Cell Lymphoma. <i>PLoS ONE</i> , 2013, 8, e68915.	2.5	87
6	The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 149, 575-584.	1.4	85
7	Bipolar Tumor-Associated Macrophages in Ovarian Cancer as Targets for Therapy. <i>Cancers</i> , 2018, 10, 366.	3.7	78
8	Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer. <i>Journal of Ovarian Research</i> , 2015, 8, 46.	3.0	44
9	The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells. <i>Cancer Biology and Therapy</i> , 2011, 12, 484-493.	3.4	42
10	Homologous recombination deficiency real-time clinical assays, ready or not?. <i>Gynecologic Oncology</i> , 2020, 159, 877-886.	1.4	39
11	HPV vaccine use among African American girls: Qualitative formative research using a participatory social marketing approach. <i>Gynecologic Oncology</i> , 2014, 132, S13-S20.	1.4	38
12	<i>KRAS</i> Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine. <i>Cancer Research</i> , 2015, 75, 2897-2906.	0.9	37
13	The Therapeutic Potential of Class I Selective Histone Deacetylase Inhibitors in Ovarian Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 111.	2.8	35
14	Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. <i>Oncotarget</i> , 2015, 6, 21353-21368.	1.8	35
15	Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 127, 579-586.	1.4	34
16	Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth. <i>Cancer Letters</i> , 2015, 368, 79-87.	7.2	32
17	CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes. <i>Gynecologic Oncology</i> , 2020, 157, 405-410.	1.4	30
18	Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer. <i>Molecular Cancer</i> , 2015, 14, 192.	19.2	29

#	ARTICLE	IF	CITATIONS
19	Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib. <i>Gynecologic Oncology</i> , 2016, 143, 143-151.	1.4	29
20	Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells. <i>Molecular Cancer Research</i> , 2015, 13, 1197-1205.	3.4	25
21	Ascites-induced compression alters the peritoneal microenvironment and promotes metastatic success in ovarian cancer. <i>Scientific Reports</i> , 2020, 10, 11913.	3.3	25
22	Increasing Area Deprivation Index negatively impacts ovarian cancer survival. <i>Cancer Epidemiology</i> , 2021, 74, 102013.	1.9	21
23	Early Detection of Treatment-Induced Mitotic Arrest Using Temporal Diffusion Magnetic Resonance Spectroscopy. <i>Neoplasia</i> , 2016, 18, 387-397.	5.3	20
24	Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer. <i>Cancers</i> , 2018, 10, 296.	3.7	20
25	Examination of Intersectionality and the Pipeline for Black Academic Surgeons. <i>JAMA Surgery</i> , 2022, 157, 327.	4.3	20
26	Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors. <i>Journal of Ovarian Research</i> , 2018, 11, 17.	3.0	18
27	Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 162, 163-172.	1.4	18
28	Blood type, ABO genetic variants, and ovarian cancer survival. <i>PLoS ONE</i> , 2017, 12, e0175119.	2.5	17
29	A Case of Extrauterine Endometrial Stromal Sarcoma in the Colon Diagnosed Three Decades after Hysterectomy for Benign Disease. <i>Case Reports in Obstetrics and Gynecology</i> , 2013, 2013, 1-3.	0.3	16
30	Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer. <i>BMC Cancer</i> , 2020, 20, 970.	2.6	16
31	Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer. <i>Neoplasia</i> , 2022, 24, 63-75.	5.3	14
32	Pragmatic trial of an intervention to increase human papillomavirus vaccination in safety-net clinics. <i>BMC Public Health</i> , 2017, 17, 158.	2.9	13
33	Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer. <i>BMC Cancer</i> , 2022, 22, 497.	2.6	13
34	An orthotopic model of platinum-sensitive high grade serous fallopian tube carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2012, 5, 37-45.	0.5	12
35	Preferential Effect of Akt2-Dependent Signaling on the Cellular Viability of Ovarian Cancer Cells in Response to EGF. <i>Journal of Cancer</i> , 2014, 5, 670-678.	2.5	11
36	Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records. <i>BMC Cancer</i> , 2016, 16, 612.	2.6	11

#	ARTICLE	IF	CITATIONS
37	Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer. <i>ACS Omega</i> , 2019, 4, 9251-9261.	3.5	10
38	Augmented Serum Amyloid A1/2 Mediated by TNF-induced NF- κ B in Human Serous Ovarian Epithelial Tumors. <i>Immune Network</i> , 2017, 17, 121.	3.6	9
39	Disparities in ovarian cancer survival at the only NCI-designated cancer center in Kansas. <i>American Journal of Surgery</i> , 2021, 221, 712-717.	1.8	9
40	Pharmacological ascorbate induces α -BRCAness TM and enhances the effects of Poly(ADP-ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer. <i>Oncology Letters</i> , 2020, 19, 2629-2638.	1.8	8
41	Adrenal Gland Metastasis Is an Unusual Manifestation of Endometrial Cancer. <i>Case Reports in Surgery</i> , 2013, 2013, 1-3.	0.4	7
42	Expression of p52, a non-canonical NF- κ B transcription factor, is associated with poor ovarian cancer prognosis. <i>Biomarker Research</i> , 2020, 8, 45.	6.8	7
43	Impact of employment and insurance status on distress in gynecologic oncology patients. <i>Gynecologic Oncology</i> , 2021, 161, 477-482.	1.4	6
44	Detecting Changes in the Cervix with Raman Spectroscopy. , 2010, , .		1
45	Incidental placenta increta at the time of prophylactic hysterectomy for Lynch syndrome: Insights into individualized decision-making and surgical timing. <i>Gynecologic Oncology Reports</i> , 2015, 14, 20-22.	0.6	0
46	Abstract PO045: Inhibition of GAS6/AXL improves efficacy of HER2 inhibitor trastuzumab in uterine serous cancer. , 2021, , .		0
47	A Race-Conscious Analysis of the Use of Transvaginal Ultrasonography in the Evaluation of Postmenopausal Bleeding. <i>JAMA Oncology</i> , 2021, 7, 1165.	7.1	0